https://www.selleckchem.com/products/azd3514.html
Epistaxis is the greatest cause of morbidity in patients with hereditary hemorrhagic telangiectasia (HHT); because of this, a validated epistaxis-specific quality-of-life instrument for HHT should be made available. To develop and validate an epistaxis-specific quality-of-life patient-reported outcome measure for HHT. This survey study focused on the development and validation of the Nasal Outcome Score for Epistaxis (NOSE) in HTT (NOSE HHT) outcome measure with data prospectively collected from December 10, 2019, to March 15, 2020. A t
Respect!
Kommentar
Delen
